信達生物(01801.HK)抗VEGF藥物IBI302二期臨床研究完成首例給藥
信達生物(01801.HK)公布,旗下的眼科抗VEGF-補體雙靶點藥物(IBI302),第二期臨床研究完成首例患者給藥。
該研究評估IBI302雙靶點藥物,治療繼發於新生血管性年齡相關性黃斑變性(nAMD)的有效性與安全性。信達生物醫學科學與戰略特病部執行總監錢鐳表示,IBI302作為1類新藥獲得國家科技部重大新藥專項課題的支持,旨在通過增加額外的靶點,提供更有針對性的治療和干預。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.